loader image
Thursday, January 8, 2026
78.1 F
McAllen
- Advertisement -

From Mild Cognitive Impairment to Alzheimer’s 

Translate to Spanish or other 102 languages!

How can we predict who will progress to Alzheimer’s from mild cognitive impairment. Image for illustration purposes
How can we predict who will progress to Alzheimer’s from mild cognitive impairment. Image for illustration purposes

Medical News Today

- Advertisement -
  • Dementia affects more than 55 million people worldwide, costing around $1.3 trillion per year.
  • The most common form of dementia, Alzheimer’s disease, affects up to 70% of these people.
  • New treatments are most effective if started early in the progression of the disease, but diagnosis is difficult at this stage as early symptoms are often dismissed as normal changes due to aging.
  • Now, a new study has developed a deep learning framework that can identify the risk of progressing from mild cognitive impairment to Alzheimer’s.

In 2019, according to the Global Burden of Diseases, Injuries, and Risk Factors StudyTrusted Source, an estimated 57.4 million people worldwide had dementia.

Follow the link below to read the entire article on Medical News Today: 

https://www.medicalnewstoday.com/articles/from-mild-cognitive-impairment-to-alzheimers-predicting-risk?utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2023-08-10&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Wegovy® Pill, First Oral GLP‑1 for Weight Loss, Now Available Nationwide

Wegovy® pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine in a pill for the first time.

Historic Reset of U.S. Nutrition Policy with New Food Pyramid

Mega Doctor News WASHINGTON, D.C. – U.S. Department of Health and Human Services...

Metabolic Trigger Identified That Shuts Down Key Tumor‑Fighting Gene

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to researchers from The University of Texas MD Anderson Cancer Center. 

Dry January Participation Linked to Noticeable Health Improvements

Mega Doctor News Medical News Today In 2013, Alcohol Change UK started the “Dry...
- Advertisement -
×